Regeneron Pharmaceuticals Inc.

05/15/2024 | Press release | Distributed by Public on 05/15/2024 16:11

Statement of Changes in Beneficial Ownership - Form 4

Ownership Submission
FORM 4
Check this box if no longer subject to Section 16, Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287Expires:January 31, 2005Estimated average burden hours per response...0.5
1. Name and Address of Reporting Person *
SCHLEIFER LEONARD S
2. Issuer Name and Ticker or Trading Symbol
REGENERON PHARMACEUTICALS, INC. [REGN]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
Bd. Co-Chair, President & CEO /
(Last) (First) (Middle)
777 OLD SAW MILL RIVER ROAD
3. Date of Earliest Transaction (Month/Day/Year)
(Street)
TARRYTOWN NY 10591
4. If Amendment, Date Original Filed(Month/Day/Year)
6. Individual or Join/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City) (State) (Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code 4. Securities Acquired (A) or Disposed of (D) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) 6. Ownership Form: Direct (D) or Indirect (I) 7. Nature of Indirect Beneficial Ownership
Code V Amount (A) or (D) Price
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code 5. Number of Derivative Securities Acquired (A) or Disposed of (D) 6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security 8. Price of Derivative Security 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) 11. Nature of Indirect Beneficial Ownership
Code V (A) (D) Date Exercisable Expriation Date Title Amount or Number of Shares

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
SCHLEIFER LEONARD S
777 OLD SAW MILL RIVER ROAD

TARRYTOWN, NY10591
X
Bd. Co-Chair, President & CEO

Signatures

/s/**Leonard S. Schleifer 2024-05-15
**Signature of Reporting Person Date

Explanation of Responses:

(*) If the form is filed by more than one reporting person, see Instruction 5(b)(v).
(**) Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 5, 2024.
(2) Represents volume-weighted average price of sales of 22,698 shares of Company stock on May 14, 2024 at prices ranging from $979.00 to $979.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 14, 2024 at each separate price.
(3) Represents volume-weighted average price of sales of 2,302 shares of Company stock on May 14, 2024 at prices ranging from $980.00 to $980.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 14, 2024 at each separate price.
(4) Represents volume-weighted average price of sales of 7,864 shares of Company stock on May 15, 2024 at prices ranging from $979.00 to $979.50. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 15, 2024 at each separate price.
(5) Represents volume-weighted average price of sales of 295 shares of Company stock on May 15, 2024 at prices ranging from $980.17 to $980.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 15, 2024 at each separate price.
(6) Represents volume-weighted average price of sales of 1,081 shares of Company stock on May 15, 2024 at prices ranging from $981.09 to $981.90. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 15, 2024 at each separate price.
(7) Represents volume-weighted average price of sales of 235 shares of Company stock on May 15, 2024 at prices ranging from $982.31 to $982.68. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 15, 2024 at each separate price.
(8) Represents volume-weighted average price of sales of 250 shares of Company stock on May 15, 2024 at prices ranging from $983.82 to $983.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 15, 2024 at each separate price.
(9) Represents volume-weighted average price of sales of 305 shares of Company stock on May 15, 2024 at prices ranging from $984.00 to $984.02. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 15, 2024 at each separate price.
(10) Represents volume-weighted average price of sales of 281 shares of Company stock on May 15, 2024 at prices ranging from $985.13 to $985.84. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 15, 2024 at each separate price.
(11) Represents volume-weighted average price of sales of 103 shares of Company stock on May 15, 2024 at prices ranging from $986.37 to $986.96. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 15, 2024 at each separate price.
(12) Represents volume-weighted average price of sales of 228 shares of Company stock on May 15, 2024 at prices ranging from $987.31 to $987.63. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 15, 2024 at each separate price.
(13) Represents volume-weighted average price of sales of 299 shares of Company stock on May 15, 2024 at prices ranging from $988.00 to $988.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 15, 2024 at each separate price.
(14) The stock option award vests in four equal annual installments, commencing one year after the date of grant.
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.